Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Gross Margin (2016)

Viridian Therapeutics, Inc.\DE has reported Gross Margin over the past 3 years, most recently at 35.95% for Q4 2016.

  • Quarterly results put Gross Margin at 35.95% for Q4 2016, down 6676.0% from a year ago — trailing twelve months through Dec 2016 was 30.14% (up 2746.0% YoY), and the annual figure for FY2016 was 26.72%, up 2412.0%.
  • Gross Margin for Q4 2016 was 35.95% at Viridian Therapeutics, Inc.\DE, down from 36.0% in the prior quarter.
  • Over the last five years, Gross Margin for VRDN hit a ceiling of 94.82% in Q2 2014 and a floor of 367.94% in Q4 2014.
  • Median Gross Margin over the past 3 years was 33.4% (2015), compared with a mean of 3.49%.
  • Peak annual rise in Gross Margin hit 39874bps in 2015, while the deepest fall reached -10218bps in 2015.
  • Viridian Therapeutics, Inc.\DE's Gross Margin stood at 367.94% in 2014, then surged by 108bps to 30.8% in 2015, then tumbled by -217bps to 35.95% in 2016.
  • The last three reported values for Gross Margin were 35.95% (Q4 2016), 36.0% (Q3 2016), and 43.68% (Q2 2016) per Business Quant data.